SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Amgen chases $3bn biosimilar market with three new programs, biomanufacturing capabilities

Despite plans to lay off more than 2,000 employees, Amgen is preparing for a biosimilar onslaught and expanding its portfolio to nine biosimilar programs.

Amgen targets biosimilars market

BioSilta hopes to grow growth systems business with new UK headquarters

The UK beats Finland for business opportunities according to the CEO of microbial growth system developer BioSilta, who said moving the firm to St. Ives, Cambridgeshire has improved its access to larger markets.

Sanofi's US-based CEO Viehbacher resigns after board votes to remove him

Sanofi’s board of directors has voted to remove CEO Christopher Viehbacher.

Swissmedic OKs trial of GSK's adenovirus-based Ebola vaccine

Swiss approval for a trial of an a Ebola vaccine candidate developed by GSK has been welcomed by the World Health Organisation (WHO).

Fujifilm to buy BARDA contractor Kalon Therapeutics

Texas, US-based GSK influenza vaccine partner Kalon Therapeutics has agreed to a takeover by Japanese conglomerate Fujifilm.

CSL pays $275m to acquire Novartis’ flu vaccines, three manufacturing sites

CSL Limited has agreed to acquire Novartis’ flu vaccine business for $275m (€216m), which includes manufacturing facilities in the US, UK and Germany.

dispatches from bioprocess international

Pall, Thermo Scientific, Fujifilm, Merck Millipore unveil new upstream, downstream offerings

The products, unveiled at BioProcess International in Boston this week, will help industry with their upstream and downstream processing and include an anti-CHO host cell protein detection kit, the first single-use fermentor, and a new mammalian expression platform.

Spotlight

Greenpeace: Industry needs greener disposal for single-use systems

Greenpeace: Industry needs greener disposal methods for single-use systems

Common environmentally practices for single-use systems must be adapted before industry “becomes too set in its ways,”...

Seattle Genetics, Genmab enter ADC collaboration worth up to $211m

Seattle Genetics, Genmab enter ADC collaboration worth up to $211m

Seattle Genetics and Genmab have entered into another antibody-drug conjugate (ADC)partnership under which Genmab will pay $11m...

Purple not the new orange: US FDA biopharmaceuticals list lacks dates

Purple not yet the new orange: US FDA biopharmaceuticals list lacks dates

A new list of biopharmaceuticals published by the US FDA provides limited information with only the entries...

Better together? Biosimilars sector says aye
infographic feature

Better together? biosimilars sector says aye

Partnerships are a mixed bag.For every oppressed group yearning to throw off the yoke of their imperialist...

Shifting pipelines drive AMRI to expand protein expression services

Shifting pipelines drive AMRI to expand protein expression services

AMRI has added protein expression and purification services to its drug discovery services citing the shift in...

Asthma: It’s a mAb, mAb, mAb, mAb world says analyst

Asthma: It’s a mAb, mAb, mAb, mAb world says analyst

Sanofi and Regeneron may overtake Roche and Astrazeneca at the head of the increasingly monoclonal antibody (mAb)...

On demand Supplier Webinars

Biosimilars: developing, manufacturing and selling
William Reed Business Media
All supplier webinars